Abeona Therapeutics Inc. · NASDAQ:ABEO
Abeona Therapeutics — Q2 2026 Earnings Presentation
22 slides from Abeona Therapeutics's earnings presentation, Aug 13, 2026
Slide 1: Investor Presentation
INVESTOR PRESENTATION June 2026
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains certain statements that are forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and that involve risks and uncertainties. We have attempt
Slide 3: Abeona, a Commercial-Stage, Cell and Gene Therapy Company
Abeona, a Commercial-Stage, Cell and Gene Therapy Company Anchored by Combination of in-house With expansion into Experienced ZEVASKYN®, cGMP manufacturing, solid tumor oncology leadership team with an FDA-approved, ex- regulatory expertise, with ABO-701 and decades of experience in vivo autologous
Slide 4: Pipeline
Pipeline PRECLINICAL PHASE 1/2 PHASE 3 APPROVED PSMA-SIR-T* Advanced Prostate Cancer 4 * Transaction was completed in Q1 26 **Partnered with *Ultragenyx Pharmaceutical Inc, ***Taysha Gene Therapies, Inc, **** Beacon Therapeutics.
Slide 5: ZEVASKYN for Recessive Dystrophic Epidermolysis Bullosa (RDEB)
ZEVASKYN® for Recessive Dystrophic Epidermolysis Bullosa (RDEB) Differentiated profile with transformational potential • Demonstrated wound healing and pain reduction • Sustained clinical benefit and no treatment-related serious AEs over 12 years of follow-up Commercial asset • Launch momentum for Z
Slide 6: Recessive Dystrophic Epidermolysis Bullosa (RDEB) Overview
Recessive Dystrophic Epidermolysis Bullosa (RDEB) Overview • Rare and debilitating monogenic skin disease • Caused by mutations in both copies of COL7A1 gene, resulting in lack of collagen VII, a protein necessary to keep skin intact • Leads to fragile skin that blisters easily • RDEB wounds can lea
Slide 7: First and Only Gene Therapy Made From Patients' Own Skin Cells to Treat Wounds
First and Only Gene Therapy Made From Patients’ Own Skin Cells to Treat Wounds in Children and Adults with RDEB • Single treatment application • Covers large wound areas • Provides years of healing & pain relief Geovanna, a ZEVASKYN patient at age 8 7
Slide 8: ZEVASKYN: Ex-Vivo Autologous Gene-Corrected Breakthrough Therapy for Large and Chronic Wounds
ZEVASKYN®: Ex-Vivo Autologous Gene-Corrected Breakthrough Therapy for Large and Chronic Wounds ZEVASKYN READY FOR PATIENTS Two 8 mm skin biopsies 5 1 shipped to Abeona, produces up to 12 ~40 cm2 sheets Keratinocyte cells expanded, prepared for next step Continued 3 2 ZEVASKYN Restores cell maturatio
Slide 9: Up to 12 ZEVASKYN Sheets Can Be Applied in One Surgical Session
Up to 12 ZEVASKYN® Sheets Can Be Applied in One Surgical Session ZEVASKYN sheets can be joined together to treat Two 0.8 cm up to 12 larger wounds on your front, back, or sides, or used punch biopsies ZEVASKYN ® sheets individually for smaller wounds up to 12 ZEVASKYN sheets ZEVASKYN cellular sheet
Slide 10: ZEVASKYN Cumulative Clinical Trials Experience
ZEVASKYN® Cumulative Clinical Trials Experience Durable wound Favorable long-term healing and reduction safety profile in pain and itch # Treated # wounds Study patients treated cl Phase 1/2a 7 42 • Wound healing and reduction of pain • No serious adverse events (SAEs) and itch seen with treatment,
Slide 11: Significant Wound Healing and Reduction in Pain Reported With ZEVASKYN
Significant Wound Healing and Reduction in Pain1 Reported With ZEVASKYN® Phase 3 VIITAL study topline results: • ZEVASKYN evaluated in 43 Wound healing Pain reduction from baseline at Week 24 from baseline at Week 24 randomized large chronic wound pairs and 14 non- Co-primary endpoint Co-primary end
Slide 12: Example RDEB Wounds Before and After ZEVASKYN Treatment
Example RDEB Wounds Before and After ZEVASKYN® Treatment Source: Phase 3 VIITAL study patient; wounds scored as at least75% healing at week24; individual results vary 12 Wound healing scoring was Investigator-assessed per predefinedcriteria.
Slide 13: Multi-Year Wound Healing and Pain Reduction After Single Application in Phase 1/2a
Multi-Year Wound Healing and Pain Reduction After Single Application of ZEVASKYN® in Phase 1/2a study % treated wounds with % treated wounds with pain ≥50% or ≥75% healing (n/N) (20/38) 100% 53% 90% ≥50% ≥75% 80% 70% 60% 50% 40% (6/38) 30% 16% (3/38) (2/38) 20% 8% (0/38) 5% (0/26) (0/15) (0/15) (0/5
Slide 14: Multi-Year Wound Healing After One-Time Zevaskyn Application
Multi-Year Wound Healing After One-Time Zevaskyn Application Baseline Day 7 Year 2 Year 5 Upper back Upper back Upper back Upper back Source: Phase 1/2a study patient (So et al. Orphanet Journal of Rare Diseases (2022) 17:377); individual results vary 14 Wound healing scoring was Investigator-assess
Slide 15: Presentation at SID2026 on Sustained Wound Healing and Long-term Safety
Presentation at SID2026 on Sustained Wound Healing and Long-term Safety: 12-year Case Report and 5-year Phase 3 Data (below) and 12-year Case Report Individual results may vary 15 Eid E et al. "Sustained wound healing and long-term safety of prademagenezamikeracel in recessivedystrophic epidermolysi
Slide 16: Significant US Commercial Opportunity for ZEVASKYN
Significant US Commercial Opportunity for ZEVASKYN® ~1,300 US DEB patients1; ~750 RDEB ZEVASKYN-eligible patients Anticipate average 2 treatment cycles per patient to cover impacted body areas (~1,500 treatment opportunities) $3.1M WAC per each treatment; >$4B cumulative revenue opportunity in the U
Slide 17: Expanded QTC Network Enhances Patient Access
Expanded QTC Network Enhances Patient Access 17 17
Slide 18: Leveraging Cell Therapy Core Competencies to Advance A Novel Pipeline
Leveraging Cell Therapy Core Competencies to Advance A Novel Pipeline TM PSMA SIR-T for Advanced Prostate Cancer 18
Slide 19: PSMA SIR-T Has the Potential To Unlock Cell Therapy For Prostate Cancer Patients
PSMA SIR-TTM Has the Potential To Unlock Cell Therapy For Prostate Cancer Patients With A High Unmet Need • PSMA is a validated target in prostate cancer, but CAR-Ts and other immunotherapies targeting PSMA have failed to deliver durable efficacy and acceptable safety profiles • PSMA SIR-TTM is a ra
Slide 20: Synthetic Immune Receptor Combines the Best of CAR and TCR
Synthetic Immune Receptor Combines the Best of CAR and TCR • Designed to overcome the fundamental limitations of CARs SIR-T TM • Retains the full signaling strength, complexity, and physiological regulation of a TCR • Exceptional in vivo responses vs. CAR T cells in preclinical models, with less in
Slide 21: PSMA-SIR-T Demonstrated Better Tumor Remission and Durability Compared to CAR Controls
PSMA-SIR-TTM Demonstrated Better Tumor Remission and Durability Compared to CAR Controls with the Same PSMA Binding Domain IND Submission & Phase 1 clinical trial initiation planned in 2H 2027 CAR controls 21 Preclinical data generated in prostate tumor-bearing mice.
Slide 22: Anchored by ZEVASKYN and Unique Capabilities to Commercialize Complex Genetic Medicines
® Anchored by ZEVASKYN and Unique Capabilities to Commercialize Complex Genetic Medicines, Abeona is Poised to Break Out Significant support $8.7M* net product Pipeline expansion of ZEVASKYN® revenue Q1 2026, an into solid tumor from the RDEB increase of $6.3M oncology with community and Quarter ove